JP2019514844A - 抗ｃｄ７３抗体を用いた併用療法 - Google Patents

抗ｃｄ７３抗体を用いた併用療法 Download PDF

Info

Publication number
JP2019514844A
JP2019514844A JP2018546508A JP2018546508A JP2019514844A JP 2019514844 A JP2019514844 A JP 2019514844A JP 2018546508 A JP2018546508 A JP 2018546508A JP 2018546508 A JP2018546508 A JP 2018546508A JP 2019514844 A JP2019514844 A JP 2019514844A
Authority
JP
Japan
Prior art keywords
seq
antibody
cdr2
human
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018546508A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019514844A5 (cg-RX-API-DMAC7.html
Inventor
ブライアン・シー・バーンハート
アラン・ジェイ・コーマン
ニルス・ロンバーグ
アーロン・ピー・ヤムニウク
モハン・スリニバサン
カーラ・エイ・ヘニング
ミン・レイ
エマヌエラ・セガ
アンジェラ・グッドイナフ
マリア・ジュア−クンケル
グオドン・チェン
ジョン・エス・サック
リチャード・ワイ・ホアン
マーティン・ジェイ・コーベット
ジョセフ・イー・マイヤーズ・ジュニア
リアン・シュヴァイツァー
サンドラ・ブイ・ハッチャー
レイチェル・アルトゥラ
ハイチュン・ホアン
ピンピン・ジャン
エドワード・ジェイ・ヒルト
マイケル・ネイサン・ヘドリック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2019514844A publication Critical patent/JP2019514844A/ja
Publication of JP2019514844A5 publication Critical patent/JP2019514844A5/ja
Priority to JP2022056810A priority Critical patent/JP2022104961A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2018546508A 2016-03-04 2017-03-03 抗ｃｄ７３抗体を用いた併用療法 Pending JP2019514844A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022056810A JP2022104961A (ja) 2016-03-04 2022-03-30 抗ｃｄ７３抗体を用いた併用療法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201662303985P 2016-03-04 2016-03-04
US62/303,985 2016-03-04
US201662305378P 2016-03-08 2016-03-08
US62/305,378 2016-03-08
US201662341220P 2016-05-25 2016-05-25
US62/341,220 2016-05-25
US201662363703P 2016-07-18 2016-07-18
US62/363,703 2016-07-18
US201662431987P 2016-12-09 2016-12-09
US62/431,987 2016-12-09
PCT/US2017/020714 WO2017152085A1 (en) 2016-03-04 2017-03-03 Combination therapy with anti-cd73 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022056810A Division JP2022104961A (ja) 2016-03-04 2022-03-30 抗ｃｄ７３抗体を用いた併用療法

Publications (2)

Publication Number Publication Date
JP2019514844A true JP2019514844A (ja) 2019-06-06
JP2019514844A5 JP2019514844A5 (cg-RX-API-DMAC7.html) 2020-04-09

Family

ID=58361103

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018546508A Pending JP2019514844A (ja) 2016-03-04 2017-03-03 抗ｃｄ７３抗体を用いた併用療法
JP2022056810A Pending JP2022104961A (ja) 2016-03-04 2022-03-30 抗ｃｄ７３抗体を用いた併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022056810A Pending JP2022104961A (ja) 2016-03-04 2022-03-30 抗ｃｄ７３抗体を用いた併用療法

Country Status (13)

Country Link
US (1) US20190284293A1 (cg-RX-API-DMAC7.html)
EP (1) EP3423494A1 (cg-RX-API-DMAC7.html)
JP (2) JP2019514844A (cg-RX-API-DMAC7.html)
KR (3) KR20180118725A (cg-RX-API-DMAC7.html)
CN (1) CN109476740A (cg-RX-API-DMAC7.html)
AU (1) AU2017228470A1 (cg-RX-API-DMAC7.html)
BR (1) BR112018067368A2 (cg-RX-API-DMAC7.html)
CA (1) CA3016187A1 (cg-RX-API-DMAC7.html)
EA (1) EA201891983A8 (cg-RX-API-DMAC7.html)
IL (2) IL295230A (cg-RX-API-DMAC7.html)
MX (1) MX2018010473A (cg-RX-API-DMAC7.html)
SG (2) SG10201913033UA (cg-RX-API-DMAC7.html)
WO (1) WO2017152085A1 (cg-RX-API-DMAC7.html)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023509448A (ja) * 2020-01-03 2023-03-08 インサイト・コーポレイション 抗ｃｄ７３抗体及びその使用
JP2023522365A (ja) * 2020-04-22 2023-05-30 アケソ・バイオファーマ・インコーポレイテッド 抗ｃｄ７３抗体とその利用
JP2023522730A (ja) * 2020-04-22 2023-05-31 アケソ・バイオファーマ・インコーポレイテッド 抗ｃｄ７３／抗ｐｄ－１二重特異性抗体及びその使用
JP2023532234A (ja) * 2020-06-22 2023-07-27 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド 抗ｃｄ７３抗体とその用途
JP2023538369A (ja) * 2020-08-17 2023-09-07 アケソ バイオファーマ カンパニー，リミティド 抗ｃｄ７３抗体とその使用
JP2023546743A (ja) * 2020-10-23 2023-11-07 中山康方生物医▲藥▼有限公司 抗ｃｄ７３抗体及びその使用
JP2023554326A (ja) * 2020-12-11 2023-12-27 上海華奥泰生物藥業股▲フン▼有限公司 Ｃｄ７３の抗原結合蛋白及びその使用
JP2024502758A (ja) * 2021-01-13 2024-01-23 上海華奥泰生物藥業股▲フン▼有限公司 Ｃｄ７３結合タンパク質及びその使用

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6847037B2 (ja) * 2014-11-11 2021-03-24 メディミューン リミテッド 抗ｃｄ７３抗体とａ２ａ受容体阻害薬とを含む併用治療薬及びその使用
WO2016081746A2 (en) 2014-11-21 2016-05-26 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
ES2807182T3 (es) 2014-11-21 2021-02-22 Bristol Myers Squibb Co Anticuerpos frente a CD73 y sus usos
WO2018071500A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
EP3630833A1 (en) * 2017-05-25 2020-04-08 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
CN110785187B (zh) 2017-06-22 2024-04-05 诺华股份有限公司 针对cd73的抗体分子及其用途
JP2021502342A (ja) * 2017-11-06 2021-01-28 コーバス・ファーマシューティカルズ・インコーポレイテッド 癌処置のためのアデノシン経路阻害剤
CA3080994A1 (en) * 2017-11-06 2019-05-09 Corvus Pharmaceuticals, Inc. Combination therapy for cancer treatment
EP3737696A1 (en) * 2018-01-12 2020-11-18 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
CA3090008A1 (en) * 2018-03-09 2019-09-12 Phanes Therapeutics, Inc. Anti-cd73 antibodies and uses thereof
CA3093468A1 (en) 2018-03-09 2019-09-12 Agenus Inc. Anti-cd73 antibodies and methods of use thereof
JP7417530B2 (ja) 2018-03-09 2024-01-18 アーカス バイオサイエンシズ インコーポレイティド 優先投与される免疫増強薬
WO2019175222A1 (en) * 2018-03-13 2019-09-19 Tusk Therapeutics Ltd Anti-cd25 for tumour specific cell depletion
JP7611700B2 (ja) 2018-03-27 2025-01-10 ブリストル－マイヤーズ スクイブ カンパニー 紫外線シグナルを使用した力価のリアルタイムモニタリング
KR20200142542A (ko) * 2018-04-12 2020-12-22 브리스톨-마이어스 스큅 컴퍼니 Cd73 길항제 항체 및 pd-1/pd-l1 축 길항제 항체에 의한 항암 조합 요법
EP3569618A1 (en) * 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
AU2019297361B2 (en) 2018-07-05 2024-06-27 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
MX2021005396A (es) 2018-11-12 2021-07-06 Jiangsu Hengrui Medicine Co Anticuerpo anti-cd73, fragmento de union a antigeno y aplicacion del mismo.
CN111499747B (zh) * 2019-01-11 2022-03-18 康诺亚生物医药科技（成都）有限公司 一种抗cd73单克隆抗体及其应用
AU2020205753B2 (en) 2019-01-11 2025-05-29 Omeros Corporation Methods and compositions for treating cancer
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2020172658A1 (en) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Methods of isolating a protein
WO2020185859A1 (en) 2019-03-12 2020-09-17 Arcus Biosciences, Inc. Treatment of oncogene-driven cancers
EP3947463A4 (en) * 2019-03-29 2022-12-21 Arcus Biosciences, Inc. CANCER TREATMENT USING AN IDENTIFIED ADENOSINE IMPRESSION
EP3947447A4 (en) * 2019-04-02 2023-01-11 Medimmune, LLC ANTI-CD73, ANTI-PD-L1 ANTIBODIES AND CHEMOTHERAPY FOR THE TREATMENT OF TUMORS
EP3973274A1 (en) 2019-05-23 2022-03-30 Bristol-Myers Squibb Company Methods of monitoring cell culture media
CN112300279A (zh) * 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 针对抗cd73抗体和变体的方法和组合物
MX2022005866A (es) * 2019-11-15 2022-08-15 Genzyme Corp Anticuerpos biparatopicos frente a cd73.
JP2023509442A (ja) 2020-01-03 2023-03-08 インサイト・コーポレイション Ｃｄ７３阻害剤とａ２ａ／ａ２ｂアデノシン受容体阻害剤の併用療法
CN113248611A (zh) * 2020-02-13 2021-08-13 湖南华康恒健生物技术有限公司 抗bcma抗体、其药物组合物及应用
WO2021205383A1 (en) * 2020-04-09 2021-10-14 Aprilbio Co., Ltd. Monoclonal antibodies and antigen binding fragments thereof for suppressing cd73 immune checkpoint and uses thereof
WO2021247188A1 (en) 2020-06-05 2021-12-09 Bristol-Myers Squibb Company Cd73 antagonist potency assay and methods of use thereof
WO2022012639A1 (zh) * 2020-07-16 2022-01-20 和铂医药(上海)有限责任公司 Pd-1抗原结合蛋白及其应用
CA3194926A1 (en) * 2020-09-23 2022-03-31 Medimmune, Llc Treatment methods using anti-cd73 and anti-pd-l1 antibodies and chemotherapy
US20230374064A1 (en) 2020-10-05 2023-11-23 Bristol-Myers Squibb Company Methods for concentrating proteins
AU2021411952A1 (en) * 2020-12-29 2023-08-10 Incyte Corporation Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies
WO2023143227A1 (zh) * 2022-01-25 2023-08-03 石药集团巨石生物制药有限公司 抗cd73抗体及应用
US12187806B2 (en) 2022-03-04 2025-01-07 Development Center For Biotechnology Anti-CD73 antibodies and use thereof
KR20240156411A (ko) 2022-03-09 2024-10-29 브리스톨-마이어스 스큅 컴퍼니 치료 단백질의 일시적 발현
US20250352645A1 (en) * 2022-05-26 2025-11-20 I-Mab Biopharma Co., Ltd. Biomarkers and methods for treating nsclc
WO2023230605A1 (en) * 2022-05-26 2023-11-30 I-Mab Biopharma Co., Ltd. A method of treating solid tumor
WO2023227115A1 (en) * 2022-05-26 2023-11-30 I-Mab Biopharma Co., Ltd. A method of treating solid tumor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015042246A1 (en) * 2013-09-20 2015-03-26 Bristol-Myers Squibb Company Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors

Family Cites Families (199)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
CA2156924A1 (en) 1993-12-27 1995-07-06 Ton That Hai Water soluble non-immunogenic polyamide cross-linking agents
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
NZ321172A (en) 1995-10-03 2000-02-28 Scripps Research Inst CBI analogs of CC-1065 and the duocarmycins
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO1998042752A1 (en) 1997-03-21 1998-10-01 Brigham And Women's Hospital Inc. Immunotherapeutic ctla-4 binding peptides
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
EP1068241B1 (en) 1998-04-02 2007-10-10 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
JP4118462B2 (ja) 1999-07-19 2008-07-16 株式会社リコー 携帯電子機器
EP1074563A1 (en) 1999-08-02 2001-02-07 F. Hoffmann-La Roche Ag Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof
IL148021A0 (en) 1999-08-23 2002-09-12 Dana Farber Cancer Inst Inc Novel b7-4 molecules and uses therefor
WO2001014424A2 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
AU784634B2 (en) 1999-11-30 2006-05-18 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
WO2002092780A2 (en) 2001-05-17 2002-11-21 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
US7087600B2 (en) 2001-05-31 2006-08-08 Medarex, Inc. Peptidyl prodrugs and linkers and stabilizers useful therefor
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
ATE536188T1 (de) 2002-08-14 2011-12-15 Macrogenics Inc Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
EP1553975B8 (en) 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
EP1562972B1 (en) 2002-10-15 2010-09-08 Facet Biotech Corporation ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS
ES2897506T3 (es) 2003-01-09 2022-03-01 Macrogenics Inc Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos
KR101424624B1 (ko) 2003-05-14 2014-07-31 이뮤노젠 아이엔씨 약물 콘쥬게이트 조성물
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
KR101520209B1 (ko) 2003-11-06 2015-05-13 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
PL1706424T3 (pl) 2004-01-12 2010-04-30 Mentrik Biotech Llc Warianty regionu Fc
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
US7778814B2 (en) 2004-03-30 2010-08-17 Siemens Aktiengesellschaft Method and device for simulating an automation system
RU2402548C2 (ru) 2004-05-19 2010-10-27 Медарекс, Инк. Химические линкеры и их конъюгаты
JP4806680B2 (ja) 2004-05-19 2011-11-02 メダレックス インコーポレイテッド 自己犠牲リンカー及び薬剤複合体
AU2005274905B2 (en) 2004-08-04 2010-12-23 Mentrik Biotech, Llc Variant Fc regions
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
CA2588613C (en) 2004-11-23 2010-09-14 Pip Co., Ltd. Built-in wall water service box
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
DK1866339T3 (da) 2005-03-25 2013-09-02 Gitr Inc GTR-bindende molekyler og anvendelser heraf
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
EP1896582A4 (en) 2005-05-09 2009-04-08 Ono Pharmaceutical Co HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS
CN101212967A (zh) 2005-05-10 2008-07-02 因塞特公司 吲哚胺2,3-双加氧酶调节剂及其用法
ES2523666T3 (es) 2005-05-31 2014-11-28 Board Of Regents, The University Of Texas System Anticuerpos IgG1 con la parte Fc mutada para el aumento de unión al receptor FcRn y usos de los mismos
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
NZ566982A (en) 2005-09-26 2011-06-30 Medarex Inc Duocarmycin drug conjugates
WO2007038868A2 (en) 2005-10-03 2007-04-12 The University Of British Columbia Novel enediyne compound and uses thereof
EP1940789B1 (en) 2005-10-26 2011-11-23 Medarex, Inc. Methods and compounds for preparing cc-1065 analogs
US20080206246A1 (en) 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
CA2627190A1 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
ES2540561T3 (es) 2005-12-20 2015-07-10 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
PE20080316A1 (es) 2006-05-25 2008-04-10 Bristol Myers Squibb Co Compuestos de aziridinil-epotilona
AR062448A1 (es) 2006-05-25 2008-11-12 Endocyte Inc Conjugados de analogos de aziridinil-epotilona y composiciones farmaceuticas que comprenden los mismos
CA2663057C (en) 2006-09-19 2015-12-08 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
AU2008218766A1 (en) 2007-02-21 2008-08-28 Medarex, Inc. Chemical linkers with single amino acids and conjugates thereof
JP2008278814A (ja) 2007-05-11 2008-11-20 Igaku Seibutsugaku Kenkyusho:Kk アゴニスティック抗ヒトｇｉｔｒ抗体による免疫制御の解除とその応用
US7867491B2 (en) 2007-05-30 2011-01-11 Genexine Co., Ltd. Immunoglobulin fusion proteins
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
DE102007036200A1 (de) 2007-08-02 2009-02-05 Knorr-Bremse Systeme für Nutzfahrzeuge GmbH Induktiver Weg- oder Drehwinkelsensor mit zwischen zwei Spulen angeordnetem Abschirmblech
EP2190861A4 (en) 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
BRPI0816014A8 (pt) 2007-10-01 2018-06-19 Bristol Myers Squibb Co anticorpo humano monoclonal isolado, composição, conjugado anticorpo-molécula parceiro, mólecula isolada de ácido nucléico, vetor de expressão, célula hospedeira, método para preparar um anticorpo anti-mesotelina, método de inibição do crescimento de uma célula tumoral expressando a mesotelina, método de tratamento do câncer em um indivíduo, anticorpo anti-mesotelina isolado, e método de inibir o crescimento de uma célula expressando a mesotelina
CN101918027A (zh) 2007-11-02 2010-12-15 森托科尔奥索生物科技公司 半合成GLP-1肽-Fc融合构造、方法及其用途
EP2229187A2 (en) 2007-11-30 2010-09-22 Bristol-Myers Squibb Company Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (ptk7)
AR069747A1 (es) 2007-11-30 2010-02-17 Medarex Inc Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion
EP2227233B1 (en) 2007-11-30 2013-02-13 Newlink Genetics Ido inhibitors
WO2009079242A2 (en) 2007-12-05 2009-06-25 Massachusetts Institute Of Technology Aglycosylated immunoglobulin mutants
DK2808343T3 (da) 2007-12-26 2019-08-19 Xencor Inc Fc-varianter med ændret binding til FcRn
FR2927330B1 (fr) 2008-02-07 2010-02-19 Sanofi Aventis Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antagonistes des recepteurs a l'urotensine ii
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
CN102089325A (zh) 2008-04-17 2011-06-08 埃博灵克斯股份有限公司 能够结合血清白蛋白的肽，以及包含其的化合物、构建体和多肽
EP2282773B2 (en) 2008-05-02 2025-03-05 Seagen Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US20100189727A1 (en) 2008-12-08 2010-07-29 Tegopharm Corporation Masking Ligands For Reversible Inhibition Of Multivalent Compounds
TW202442680A (zh) 2008-12-09 2024-11-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
JP5843357B2 (ja) 2009-02-03 2016-01-13 アムニクス オペレーティング インコーポレイテッド 延長組換えポリペプチドおよび延長組換えポリペプチドを含む組成物
US20110007023A1 (en) 2009-07-09 2011-01-13 Sony Ericsson Mobile Communications Ab Display device, touch screen device comprising the display device, mobile device and method for sensing a force on a display device
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
IN2012DN01920A (cg-RX-API-DMAC7.html) 2009-09-03 2015-07-24 Schering Corp
ES2601226T3 (es) 2009-10-28 2017-02-14 Newlink Genetics Corporation Derivados de imidazol como inhibidores de IDO
MX343747B (es) 2009-11-24 2016-11-22 Medimmune Ltd Agentes de union diana contra b7-h1.
CN105218672A (zh) 2009-12-10 2016-01-06 霍夫曼-拉罗奇有限公司 优先结合人csf1r胞外域4的抗体及其用途
CN102711449B (zh) 2009-12-10 2015-01-07 瑞泽恩制药公司 生产重链抗体的小鼠
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
PL3095871T3 (pl) 2010-02-08 2019-10-31 Regeneron Pharma Mysz zawierająca wspólny łańcuch lekki
PT3053932T (pt) 2010-02-19 2020-10-21 Xencor Inc Novas imunoadesinas ctla4-ig
EP2982380B1 (en) 2010-03-04 2021-09-01 MacroGenics, Inc. Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
RU2617971C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
CN103068405A (zh) 2010-04-15 2013-04-24 西雅图基因公司 靶向吡咯并苯并二氮杂卓结合物
EP2558475A1 (en) 2010-04-15 2013-02-20 Spirogen Sàrl Pyrrolobenzodiazepines used to treat proliferative diseases
CN112480256A (zh) 2010-05-04 2021-03-12 戊瑞治疗有限公司 结合csf1r的抗体
ME02902B (me) 2010-06-22 2018-04-20 Regeneron Pharma Transgeni miševi sa modifikovanim lokusom endogenog lambda imunoglobulina
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
DK2614082T3 (en) 2010-09-09 2018-11-26 Pfizer 4-1BB BINDING MOLECULES
US20140010812A1 (en) 2010-12-20 2014-01-09 Rockefeller University (The) Modulating agonistic tnfr antibodies
KR20230005405A (ko) 2011-02-25 2023-01-09 추가이 세이야쿠 가부시키가이샤 ＦｃγＲＩＩｂ 특이적 Ｆｃ 항체
SI2697257T1 (sl) 2011-04-13 2017-02-28 Bristol-Myers Squibb Company FC fuzijski proteini, ki vsebujejo nove linkerje ali razmestitve
NO2694640T3 (cg-RX-API-DMAC7.html) 2011-04-15 2018-03-17
PT2699264T (pt) 2011-04-20 2018-05-23 Medimmune Llc Anticorpos e outras moléculas que ligam b7-h1 e pd-1
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
CN103987718A (zh) 2011-09-20 2014-08-13 斯皮罗根有限公司 作为非对称二聚体pbd化合物用于内含在靶向结合物中的吡咯并苯并二氮杂卓
WO2013095738A2 (en) 2011-09-27 2013-06-27 Mapp Biopharmaceutical, Inc. Monoclonal antibodies with altered affinities for human fcyri, fcyrllla, and c1q proteins
CA2853889A1 (en) 2011-12-15 2013-06-20 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
EA031715B1 (ru) 2011-12-19 2019-02-28 Дзе Рокфеллер Юниверсити ПРОТИВОВОСПАЛИТЕЛЬНЫЙ НЕСИАЛИРОВАННЫЙ ПОЛИПЕПТИД МОДИФИЦИРОВАННОГО Fc-УЧАСТКА hIgG1, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ
WO2013119716A1 (en) 2012-02-06 2013-08-15 Genentech, Inc. Compositions and methods for using csf1r inhibitors
MX350539B (es) 2012-02-13 2017-09-08 Bristol Myers Squibb Co Compuestos de enediino, conjugados de los mismos y sus usos y metodos.
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
JP2015517490A (ja) 2012-05-11 2015-06-22 ファイブ プライム セラピューティックス インコーポレイテッド コロニー刺激因子１受容体（ｃｓｆ１ｒ）を結合させる抗体を用いて状態を治療する方法
EA037351B8 (ru) 2012-05-15 2021-04-29 Бристол-Майерс Сквибб Компани Способ лечения злокачественных опухолей с использованием комбинации антител против pd-1 и ctla-4
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
BR112015004426A2 (pt) 2012-08-31 2018-08-28 Five Prime Therapeutics, Inc. método para reduzir o nível, tratar uma condição, tratar uma condição inflamatória, tratar distúrbio de cd16+, tratar um respondente inadequado de metotrexate, tratar um respondente inadequado de inibidor de tnf, indentificar um sujeito, predizer responsividade e métodos para tratar uma condição inflamatória
SG11201501741YA (en) 2012-09-13 2015-04-29 Bristol Myers Squibb Co Fibronectin based scaffold domain proteins that bind to myostatin
BR112015019432A2 (pt) 2013-02-14 2017-08-22 Bristol Myers Squibb Co Compostos de tubulisina, métodos de produção e uso
EP3204417B1 (en) 2014-10-10 2020-07-22 Innate Pharma Cd73 blockade
JP6755866B2 (ja) 2014-11-10 2020-09-16 メディミューン リミテッド Ｃｄ７３特異的結合分子及びその使用
JP6847037B2 (ja) * 2014-11-11 2021-03-24 メディミューン リミテッド 抗ｃｄ７３抗体とａ２ａ受容体阻害薬とを含む併用治療薬及びその使用
ES2807182T3 (es) * 2014-11-21 2021-02-22 Bristol Myers Squibb Co Anticuerpos frente a CD73 y sus usos
WO2016081746A2 (en) * 2014-11-21 2016-05-26 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015042246A1 (en) * 2013-09-20 2015-03-26 Bristol-Myers Squibb Company Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CLINICAL CANCER RESEARCH, vol. 19, no. 20, JPN6021007518, 2013, pages 5626 - 5635, ISSN: 0004649434 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023509448A (ja) * 2020-01-03 2023-03-08 インサイト・コーポレイション 抗ｃｄ７３抗体及びその使用
JP2023522365A (ja) * 2020-04-22 2023-05-30 アケソ・バイオファーマ・インコーポレイテッド 抗ｃｄ７３抗体とその利用
JP2023522730A (ja) * 2020-04-22 2023-05-31 アケソ・バイオファーマ・インコーポレイテッド 抗ｃｄ７３／抗ｐｄ－１二重特異性抗体及びその使用
JP7763780B2 (ja) 2020-04-22 2025-11-04 中山康方生物医▲藥▼有限公司 抗ｃｄ７３／抗ｐｄ－１二重特異性抗体及びその使用
JP2023532234A (ja) * 2020-06-22 2023-07-27 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド 抗ｃｄ７３抗体とその用途
JP2023538369A (ja) * 2020-08-17 2023-09-07 アケソ バイオファーマ カンパニー，リミティド 抗ｃｄ７３抗体とその使用
JP2023546743A (ja) * 2020-10-23 2023-11-07 中山康方生物医▲藥▼有限公司 抗ｃｄ７３抗体及びその使用
JP2023554326A (ja) * 2020-12-11 2023-12-27 上海華奥泰生物藥業股▲フン▼有限公司 Ｃｄ７３の抗原結合蛋白及びその使用
JP2024502758A (ja) * 2021-01-13 2024-01-23 上海華奥泰生物藥業股▲フン▼有限公司 Ｃｄ７３結合タンパク質及びその使用

Also Published As

Publication number Publication date
BR112018067368A2 (pt) 2019-01-15
MX2018010473A (es) 2018-09-28
AU2017228470A8 (en) 2020-04-23
US20190284293A1 (en) 2019-09-19
KR20230038311A (ko) 2023-03-17
EA201891983A1 (ru) 2019-02-28
WO2017152085A8 (en) 2020-04-16
KR20180118725A (ko) 2018-10-31
CA3016187A1 (en) 2017-09-08
WO2017152085A1 (en) 2017-09-08
EP3423494A1 (en) 2019-01-09
KR20220033522A (ko) 2022-03-16
SG11201806861SA (en) 2018-09-27
AU2017228470A1 (en) 2018-08-30
IL261395A (en) 2018-10-31
SG10201913033UA (en) 2020-03-30
JP2022104961A (ja) 2022-07-12
EA201891983A8 (ru) 2020-05-28
IL295230A (en) 2022-10-01
CN109476740A (zh) 2019-03-15

Similar Documents

Publication Publication Date Title
JP7235712B2 (ja) Ｃｄ７３に対する抗体およびその使用
JP7119051B2 (ja) Ｏｘ４０に対する抗体およびその使用
JP2022104961A (ja) 抗ｃｄ７３抗体を用いた併用療法
JP2025128184A (ja) Ｔｉｇｉｔに対する抗体
JP7762186B2 (ja) Ｔｉｍ３に対する抗体およびその使用
JP2019508013A (ja) グルココルチコイド誘発腫瘍壊死因子受容体（ｇｉｔｒ）に対する抗体およびその使用
TW201811829A (zh) 針對tim3之抗體及其用途
HK40036870A (en) Antibodies against cd73 and uses thereof
EA040561B1 (ru) Способ применения антитела к ox40 (варианты)
HK1246308B (en) Antibodies against ox40 and uses thereof
HK1244817B (en) Antibodies against cd73 and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210309

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210806

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211130